Company: NGVT
Filing Date: 2025-03-20
Form Type: DEFA14A
Source: 0001140361-25-009731
Chunk: 1

Company: Ingevity Corp
Filing Date: 2025-03-20
Form: DEFA14A
Chunk 1
---
 and engaged directors on the WHITEproxy card - Jean S. Blackwell, Luis Fernandez-Moreno, Diane H. Gulyas, Bruce D. Hoechner, Frederick J. Lynch, Karen G. Narwold, Daniel F. Sansone, J. Kevin Willis and Benjamin G. (Shon) Wright. The Company also launched VoteIngevity.com, a website including voting instructions and other resources for stockholders. Highlights from the letter include:

| • | Under the leadership of Ingevity’s Board and management team, the Company has undertaken a series of fundamental changes to the business in response to external market challenges. |

| • | Ingevity has seen the impact of these changes through its strong 2024 financial results and recent stock price performance, setting the Company up for continued momentum in 2025. |

| • | Ingevity’s Board has provided strong oversight and continued to evolve the Company’s leadership with the recent appointment of David H. Li as Ingevity’s next President and CEO, effective 
 April 7.                                                                                                                                                                                   |

| • | The Company has made meaningful efforts to reach a constructive resolution and avoid a proxy fight with Vision One, but Vision One has rejected these efforts in favor of seeking the       
 election of two nominees who have never served as public company directors or as senior executives of a publicly-traded company and have no experience in the specialty chemicals industry. |

The Company encourages stockholders to vote “FOR” ONLYIngevity’s nine directors to support the decisive actions taken by the Board and management that are driving strong performance and momentum to deliver more stockholder value, and to send a message to Vision One to drop its wasteful and unnecessary proxy fight. The full text of the letter to stockholders follows: Dear Ingevity Stockholders, We are writing to provide you a brief update regarding a number of important developments at Ingevity. Beginning in 2022, unprecedented increases in crude tall oil (“CTO”) costs combined with demand softness in our primary end-markets negatively impacted our Industrial Specialties business, our results and our ability to deliver value to our stockholders. Significant and decisive action was required. In response to these external market challenges, the Ingevity Board of Directors and management team have undertaken a series of fundamental changes to the business:

| • | Rationalized our physical footprint with the closure of our DeRidder and Crossett facilities; |

| • | Terminated long-term CTO supply